10-K: BioLargo Reports Steep Losses, Revenue Drop Amid Pooph Litigation

BioLargo, Inc. reported a significant increase in net loss and a 56% revenue decrease for fiscal year 2025, primarily driven by a credit loss from a key customer and ongoing litigation.

Summary

• BioLargo, Inc. is an innovator and solution provider in cleantech technologies, focusing on air quality, water, environmental engineering, battery energy storage, and antimicrobial medical devices.
• The company operates through whollyand partially-owned subsidiaries: ONM Environmental (odor/VOC control), BioLargo Equipment Solutions & Technologies (BEST) (water treatment), BioLargo Energy Technologies, Inc. (BETI) (battery tech), Clyra Medical Technologies, Inc. (medical products), BioLargo Engineering, Science & Technologies, LLC (BLEST) (engineering services), and BioLargo Canada, Inc. (R&D).
• Consolidated revenue for 2025 decreased by 56% to $7,765,000 from $17,779,000 in 2024.
• Net loss for 2025 significantly increased to $15,189,000 ($0.04 per share) from $4,347,000 ($0.01 per share) in 2024, a 249% increase.
• A major factor in the increased net loss was a $3,886,000 credit loss expense related to Pooph Inc.'s contractual defaults and subsequent litigation.
• ONM Environmental's revenue decreased by 62% due to the cessation of product purchases by Pooph Inc.
• BLEST's third-party service revenue increased by 96% to $1,998,000 in 2025.
• Clyra Medical did not generate revenue in 2025 or 2024 but received its first purchase order for ViaCLYR in February 2026.
• BETI and BEST did not generate revenue in 2025 as they are in development/pre-commercialization phases.
• The company used $8,297,000 cash in operations in 2025 and had $3,883,000 in cash and cash equivalents at year-end.
• The auditors' report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flow.
• The company relies on issuing equity securities (both corporate and subsidiary level) to fund operations and anticipates continued dilution for existing stockholders.
• Internal controls over financial reporting are not effective due to limited financial and personnel resources and decentralized operations, leading to a material weakness in financial closing and reporting procedures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report due to the substantial increase in net loss, significant revenue decline, and the going concern warning from auditors. While there are promising technologies, the financial instability and operational challenges, including litigation and ineffective internal controls, overshadow positive developments.

Positives

• BLEST's third-party service revenue increased by 96% to $1,998,000 in 2025, indicating growth in its engineering services division.
• Clyra Medical received its first purchase order for its ViaCLYR product in February 2026, signaling initial commercialization.
• The Aqueous Electrostatic Concentrator (AEC) for PFAS remediation has been successfully validated, demonstrated over 10,000 hours of continuous operation, and installed in Lake Stockholm, New Jersey, for municipal drinking water treatment.
• The Cellinity battery technology has had its exceptional performance claims confirmed by a third party, including safety and stability.
• The company has 34 issued patents (26 in the U.S.) and multiple applications pending, providing a foundation for its intellectual property.
• Over 90 government grants have been awarded, supporting research and development activities, particularly in Canada.
• The company has added high-profile experts to BEST's board of directors (Jeffrey Kightlinger, Sally Gutierrez, Larry Dick) to aid in securing water industry projects.

Negatives

• Consolidated revenue decreased by 56% to $7,765,000 in 2025 from $17,779,000 in 2024.
• Net loss significantly increased by 249% to $15,189,000 in 2025 from $4,347,000 in 2024.
• A $3,886,000 credit loss expense was recorded due to Pooph Inc.'s contractual defaults and unpaid royalties/product invoices.
• ONM Environmental's revenue decreased by $9,692,000 (62%) in 2025, primarily due to the loss of Pooph Inc. as its largest private-label customer.
• The company used $8,297,000 cash in operations in 2025.
• Working capital was only $51,000 at December 31, 2025.
• The auditors' report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.
• Internal controls over financial reporting are not effective, with a material weakness identified in financial closing and reporting procedures due to limited resources and decentralized operations.
• The agreement with Lincoln Park Capital Fund, LLC for equity financing expired on February 1, 2026, and the company does not intend to renew it at this time.
• The Advanced Oxidation System (AOS) development has been paused in the near term due to immature U.S. regulatory frameworks and market dominance by low-cost chemical disinfection solutions.
• The company faces intense competition from large, well-established companies in all its operational markets.
• The company's common stock is thinly traded and largely illiquid, quoted on the OTCQX rather than a national exchange.
• The company regularly issues stock or stock options in lieu of cash for operating expenses, which is dilutive to existing stockholders.
• The investment in the South Korean joint venture (Odin Co. Ltd.) was fully written off in 2025 due to impairment losses.

Risks

• Recurring Losses and Negative Cash Flow: The company has incurred net losses annually since inception and may continue to experience losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern.
• Need for Additional Financing: Significant cash requirements necessitate additional financing, which may involve selling more securities and further diluting existing stockholders.
• Limited Access to Capital Markets: Ability to access capital markets could be limited by stock market performance, interest rates, financial condition, and economic perceptions, with no assurance of obtaining acceptable terms.
• Inability to Achieve Profitability: Current sales levels are insufficient to cover financial needs, and profitability depends on successful product commercialization and market acceptance, which is uncertain.
• Dependence on Third-Party Marketing Efforts: A significant portion of revenue relies on third parties (e.g., private-label customers), over whom the company has no control regarding marketing budgets or sales efforts.
• Litigation Outcomes: Litigation, such as the ongoing dispute with Pooph Inc., is uncertain and could result in substantial payments, operational restrictions, diversion of management time, and increased costs.
• Lack of Minimum Purchase Commitments: Very few customers provide firm, long-term volume purchase commitments, leading to potential periods of limited orders and adverse effects on business.
• Supply Chain Challenges: New products may face supply chain issues, including volatility in supply and pricing of raw materials (steel, electrodes, membranes, electronic components, chemicals), potentially causing delays and affecting growth.
• Reliance on Outsourced Functions: Dependence on other companies for manufacturing, sales, or marketing means delays or failures by these parties could curtail commercialization.
• Lack of Market Acceptance: Commercial success depends on adoption of technology by end-users, which is uncertain given rapidly evolving markets and strong competition.
• Ineffective Management of Growth: Anticipated expansion requires more staffing and infrastructure, and failure to manage this effectively could adversely affect customer satisfaction and operating results.
• Regulatory Approval Requirements: Some products require difficult, time-consuming, and expensive regulatory approvals (FDA, EPA, EU), which may delay or prevent commercialization.
• Ineffective Internal Controls: Material weakness in internal controls over financial reporting due to limited financial and personnel resources and decentralized operations could adversely affect financial condition and reporting accuracy.
• Loss of Key Personnel: Future success is substantially dependent on senior management, particularly the CEO, and the inability to attract and retain qualified personnel could impair business growth.
• Inadequate Nondisclosure Agreements: Nondisclosure agreements may not effectively prevent disclosure of trade secrets, and independent discovery or unauthorized access could harm competitive position.
• Product Liability Claims: Manufacturing and marketing products for consumers and institutions expose the company to product liability claims, which could be costly and exceed insurance coverage.
• Negative Publicity: Concerns about product safety or efficacy, regardless of scientific basis, could harm sales and increase product liability claims.
• Fluctuating Revenues and Operating Results: Future operating results are likely to fluctuate due to product development delays, market acceptance, demand changes, competition, and third-party activities.
• Patent Infringement: Licensing or sale of technology may infringe on others' patent rights, leading to costly litigation, delays, or inability to commercialize.
• High Cost of Patent Maintenance: Patents are expensive to maintain and prosecute, limiting international protection and potentially reducing competitive advantage if challenged or circumvented.
• International Business Risks: Future business outside the U.S. faces risks like foreign currency fluctuations, unstable political/economic conditions, trade restrictions, tariffs, inflation, and less favorable intellectual property laws.
• Volatility of Raw Material Costs: Commodity price fluctuations for key ingredients could reduce margins or force price increases, affecting market acceptance.
• Seasonal/Weather Impact on Sales: Industrial odor control product sales are highly impacted by seasons and weather, leading to unpredictability in use and sales patterns.
• Unknown Battery Technologies/Patent Infringement: Unawareness of similar or identical liquid sodium battery technologies or patent applications could lead to infringement litigation or royalty payments.
• Strong Competition in Battery Market: The worldwide battery market is highly competitive, with well-capitalized incumbents, potentially preventing market entry or share establishment for Cellinity.
• Lack of Market for Liquid Sodium Battery: No assurance of market acceptance for Cellinity, especially if competitors offer preferred alternatives.
• Business Disruptions: Operations are vulnerable to pandemics, natural disasters, and other man-made disruptions, potentially harming revenue and increasing costs.
• Information Technology Security Threats: Reliance on IT systems and third-party MSPs, coupled with sensitive data storage, poses risks of unauthorized access, data misuse, and operational disruptions.
• Economic Uncertainties: Domestic and world events (wars, trade policies, inflation, interest rates, stock market declines) create economic uncertainties that may adversely affect business.
• Dilution from Equity Line Providers: Sales of common stock to equity line providers (like Lincoln Park) cause substantial dilution and could depress stock price.
• Thinly Traded and Illiquid Common Stock: OTCQX listing limits institutional investment and liquidity, and "penny stock" rules make selling difficult.
• Stock Price Volatility: Numerous factors beyond control can cause significant fluctuations in stock price.
• No Dividends: Stockholders will only benefit from stock appreciation, as no dividends are expected.
• Issuance of Stock/Options for Expenses: Regular issuance of securities in lieu of cash for operating expenses is dilutive.
• Potential Adverse Effects from Preferred Stock: Future issuance of preferred stock could have voting rights, liquidation preferences, and other rights senior to common stock, adversely affecting its value.

Future Outlook

The company anticipates continued net losses and negative cash flow for the foreseeable future until products gain broader market acceptance. It expects to continue using cash to advance technologies, ramp up staffing, and increase support infrastructure, necessitating ongoing equity sales and resulting in continued dilution for stockholders. ONM Environmental's revenues are expected to decrease in 2026 unless a new partner for pet-odor control products is secured. BLEST's costs and expenses are projected to remain consistent. BETI is not expected to generate revenue in 2026 as it focuses on R&D and pre-commercialization. Clyra Medical anticipates recording revenue in Q1 2026 from its first ViaCLYR purchase order, and interest expense is expected to rise due to increased debt. Management is actively negotiating a new equity line arrangement with a third party and plans to expand patent protection and invest in accounting personnel and systems to improve internal controls, subject to capital availability. International commercialization for AOS, particularly in Europe, and joint ventures for Cellinity battery manufacturing are also being explored.

Management Comments

• "We expect the highest possible honest and ethical conduct from our Senior Officers. As a Senior Officer, you are an example for other employees and we expect you, through your leadership role, to foster a culture of transparency, integrity and honesty."
• "Your responsibilities include maintaining a culture of high ethical standards and commitment to compliance and a work environment that encourages employees to raise concerns, and promptly addresses employee compliance concerns."
• "We do not expect the Pooph litigation to materially affect our other business units or growth strategy."
• "We are focused on redeploying its technology with new partners that share our commitment to quality, transparency, and integrity, and expand the reach of our proven odor-control technology into new markets, providing consumers with safe, effective, and environmentally friendly products."
• "We believe CupriDyne Clean is the number-one performing industrial odor-control product in the market, and that it offers substantial savings to our customers compared with competing products."
• "We believe we are well-positioned in the PFAS-removal market for multiple reasons."
• "We remain committed to delivering scalable, cost-effective solutions that align with evolving regulatory requirements and market demand."
• "While the AOS has demonstrated exceptional performance in both laboratory and pilot-scale testing, current U.S. regulatory frameworks have not yet matured to support broad adoption of advanced oxidation technologies for micropollutant removal."
• "We believe our Cellinity batteries will have features that far surpass comparable lithium-ion batteries, the dominant incumbent technology in the market."
• "Given the global growing demand for better batteries, and, while we are witnessing a number of current examples in which battery manufacturers have secured forward-contracts to supply batteries to its customers with backlogs of orders that amount to multiple years of production capacity, we believe our offer to partner with customers to secure needed inventory provides for a clear potential pathway to access capital, and more readily scale up production to meet demand around the world."
• "At this point, we do not intend to finance and build our own manufacturing facilities, nor would we develop in-house sales channels, although that possibility remains an option to explore if needed."
• "While the outcomes of the lawsuits are uncertain, management believes that the resolutions of these proceedings will not have a material adverse effect on the Company's financial position, results of operations, or cash flows. However, adverse outcomes could materially impact future financial results."
• "Unless a new partner is found, we expect ONM Environmental's revenues for the year ending the year ended December 31, 2026 to decrease as compared to the year ended December 31, 2025."
• "We do not believe gross profits in the year ending December 31, 2026 will be sufficient to fund our current level of operations."
• "Management intends to add accounting personnel and operating staff and more sophisticated systems in order to improve its reporting procedures and internal controls, subject to available capital."

Industry Context

StockSavvy.ai notes that BioLargo operates in high-growth cleantech sectors such as PFAS remediation, battery energy storage, and advanced antimicrobial medical devices. The PFAS crisis is a globally relevant problem creating significant market opportunities for treatment technologies, positioning BioLargo's AEC system in a critical and expanding market. The shift towards renewable energy production drives demand for long-duration energy storage, where BioLargo's Cellinity battery aims to compete with dominant lithium-ion technologies like those from Tesla, CATL, BYD, Panasonic, and LG by offering enhanced safety, sustainability, and performance. The medical and dental fields also present opportunities for antibiotic-reducing wound care solutions, aligning Clyra Medical with broader healthcare trends. However, the company faces intense competition from large, established players in each of these diverse markets, requiring substantial capital and market penetration efforts. The pause in AOS development due to immature U.S. regulatory frameworks highlights a common challenge for innovative cleantech solutions needing regulatory alignment to achieve broad market adoption, contrasting with more advanced European markets.

Comparison to Industry Standards

• The AEC system for PFAS remediation is positioned against incumbent technologies like granular activated carbon, ion-exchange, and reverse osmosis systems offered by major players such as Veolia, AECOM, Xylem, and Pentair. BioLargo claims the AEC generates only a fraction of PFAS-laden waste and often at a lower cost, with performance validated to non-detect levels, meeting and exceeding EPA standards.
• The Cellinity battery aims to surpass lithium-ion batteries from industry leaders like Tesla, CATL, BYD, Panasonic, and LG in safety (no runaway fire risks), sustainability (no rare-earth elements, domestic supply chain), and performance (virtually unlimited charge/discharge cycles, no self-discharge, increased energy efficiency/density, 10-20 year life expectancy).
• Clyra Medical's ViaCLYR product, based on Copper-Iodine Complex Solution (CICS), competes in the wound management market, aiming to reduce antibiotic reliance. Specific comparable products or companies are not detailed in the filing, but the general market includes established medical device manufacturers.
• ONM Environmental's CupriDyne Clean industrial odor control product competes against national companies such as Weaver Consulting Group, Atmos Technologies, Chemstation, and OMI Industries, with BioLargo claiming it is the "number-one performing" product offering "substantial savings."

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit by Pooph Inc. against ONM Environmental, Inc.: Filed September 11, 2025, in Orange County, California Superior Court. Allegations include Breach of Contract, Breach of Implied Covenant of Good Faith and Fair Dealing, and Declaratory Judgment, seeking unspecified damages, unjust enrichment, interest, and attorneys' fees. Arises from ONM's manufacture of pet odor-control products for Pooph and ONM's refusal to fulfill purchase orders while Pooph was in breach of contract.
• Lawsuit by BioLargo, Inc., BioLargo Life Technologies, Inc., and ONM Environmental, Inc. against Pooph, Inc., and Ikigai Marketing Works, LLC: Filed November 11, 2025, in the United States District Court, Central District of California. Allegations include patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices, and constructive fraud. Seeks an order for patent infringement, injunctions, accounting for defendants' gains/profits, compensatory damages for unpaid royalties ($1,667,292), compensatory damages for unpaid product purchases ($2,154,110), treble/exemplary damages, and costs/attorneys' fees.

Related Party Transactions

• Payment of Officer Salaries: During 2025, certain officers agreed to convert $237,000 of accrued and unpaid salary into 1,348,144 shares of common stock.
• CFO Compensation: Charles K. Dargan, II's engagement agreement was extended, with his sole compensation being options to purchase 300,000 shares of common stock annually, vesting monthly.
• Clyra Medical Guaranteed Note: The $575,000 guaranteed promissory notes issued by Clyra Medical in 2025 are guaranteed by BioLargo Inc. (the parent company and largest stockholder).
• Clyra Medical Intercompany Balances: In June 2024, BioLargo converted $741,000 owed to it by Clyra into 148,156 shares of Clyra common stock.
• BETI Stock Exchange Agreement: Investors in BETI common stock have an agreement with BioLargo to exchange BETI shares for BioLargo common stock at a 20% discount to the volume weighted average price over 20 trading days.
• Clyra Medical Series A Preferred Stock Exchange Agreement: Investors in Clyra Medical Series A Preferred Stock have an agreement with BioLargo to exchange Clyra shares (plus accrued dividends) for BioLargo common stock at a 20% discount to the volume weighted average price over 30 trading days.

Stakeholder Impact

• Shareholders: Face significant dilution from ongoing equity raises at both the parent and subsidiary levels. The substantial net loss and going concern warning indicate increased financial risk. The illiquidity of the stock on OTCQX and "penny stock" rules make selling difficult.
• Employees: Increased headcount expenses and stock option compensation indicate continued investment in personnel, but the material weakness in internal controls and financial instability could pose long-term risks to job security and compensation.
• Customers: The Pooph litigation and cessation of product supply could impact customers relying on BioLargo's private-label odor control products. Delays due to supply chain challenges for new products could affect customer satisfaction.
• Suppliers/Creditors: The company's reliance on debt financing and the going concern warning could raise concerns for creditors. The credit loss from Pooph Inc. highlights risks in customer payment.
• Regulatory Bodies: The company's commitment to ethical conduct and compliance with laws and regulations is emphasized in the Code of Ethics. The pause in AOS development due to regulatory frameworks indicates a need for alignment with regulatory bodies for market entry.

Next Steps

• Redeploy pet odor control technology with new partners after Pooph litigation.
• Continue investing in innovation for AEC technology to enhance commercial viability, improve system performance, reduce lifecycle costs, and strengthen competitive position.
• Monitor evolving regulatory trends in the U.S. and explore international commercialization opportunities for AOS, particularly in Europe.
• Focus business development efforts for AOS on strategic partnerships in the European market and domestic industrial/pharmaceutical wastewater applications.
• Advance Cellinity battery development, including designing larger battery cells for packs/modules and developing manufacturing processes for scale production and supply chain.
• Explore multiple opportunities to commercialize Cellinity batteries through joint ventures with third parties.
• Clyra Medical expects to record revenue in Q1 2026 from its first ViaCLYR product purchase order.
• Clyra Medical is working with Keystone Industries to ready at-scale manufacturing of its second wound irrigation solution product.
• BLEST needs to hire more qualified staff to meet expanding demand for customers and expected growth.
• Management is evaluating securing key man insurance for senior management.
• The company expects to expand its patent protection as capital resources permit.
• Management intends to add accounting personnel and operating staff and more sophisticated systems to improve reporting procedures and internal controls, subject to available capital.
• The company intends to continue to raise investment capital through the sale of its securities and the securities of its subsidiaries.
• Management is negotiating terms of a similar equity line arrangement with a third party.
• The company intends to seek listing on the Nasdaq Stock Market or another national stock exchange when eligible.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 249% increase in net loss, a 56% revenue decline, and a going concern warning from its auditors. The significant credit loss and ongoing litigation with a major customer (Pooph Inc.) highlight substantial operational and legal risks. While BioLargo possesses promising cleantech technologies, its current financial instability, reliance on dilutive financing, and ineffective internal controls present an unfavorable risk-reward profile for investors. The illiquidity of its OTCQX-listed stock further exacerbates investment risk.

Keywords

Cleantech, Water Treatment, PFAS Remediation, Battery Energy Storage, Odor Control, VOC Control, Medical Devices, Environmental Engineering, BioLargo, Cellinity, AEC, CupriDyne Clean, Clyra Medical, ONM Environmental, BLEST, BETI, SEC Filing, 10-K, Financial Report, Corporate Governance, Risk Factors, Intellectual Property, Litigation, Going Concern